ISSLEDOVANIE EFFEKTIVNOSTI MIKRODOZI-ROVANNOY ESTROGEN-GESTAGENNOY TERAPIIV PROFILAKTIKE POSTMENOPAUZAL'NOGO OSTEOPOROZA I KORREKTsII KLIMAKTERIChESKIKh NARUShENIY
| Autor: | L A Marchenkova, A V Dreval', I V Kryukova, M V Vishnyakova, R S Tishenina, N V Balashova, M P Rubin |
|---|---|
| Jazyk: | English<br />Russian |
| Rok vydání: | 2009 |
| Předmět: | |
| Zdroj: | Остеопороз и остеопатии, Vol 12, Iss 2, Pp 10-17 (2009) |
| Druh dokumentu: | article |
| ISSN: | 2072-2680 2311-0716 |
| DOI: | 10.14341/osteo2009210-17 |
| Popis: | Although the minimal dose of 17β-estradiol in hormone replacement regimens was originally considered to be 2 mg/day, it is now increasingly accepted that a lower dose of 1 mg/day is effective in protecting women from the detrimental effects of the menopause and has a better safety profile. The aim of this study was to investigate effectiveness and tolerability of minimal dose of hormone replacement therapy (HRT) - femoston 1/5 in postmenopausal women with spine osteopenia. Study comprised 26 postmenopausal women aged 45-65 years with T-score L2-L4 2.5 SD. Treated group consisted of 16 women (average age 54.8+5.59 years and postmenopausal age 6.81+4.59 years) received femoston 1/5 (17β-estradiol 1 mg/ daily continuously combined with dydrogesterone 5 mg/daily) for 12 months. Control group included 10 subjects (average age 56.7+4.11 years and postmenopausal age 11.5+8.09 years). BMD and biochemical parameters were measured at baseline and in 6 and 12 months and climacteric symptoms were assessed at baseline and in 1, 3, 6 and 12 months. The increase in BMD were seen in lumbar spine +5.2%, total proximal femur +2.1% and trochanter +3.1% (р |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|